A multiplex PCR test for the detection of winter viruses including SARS-CoV-2, influenza A and B, and RSV
Novacyt S.A. (AIM:NCYT) Launch of research-use-only adenovirus F41 assay
The assay has been developed by Novacyt to support research efforts following a recent increase in cases of acute hepatitis in children
Novacyt S.A. (AIM:NCYT) Approval of exsigT COVID-19 Direct test in the UK
Approval of exsig™ COVID-19 Direct test in the UK under CTDA legislation
Novacyt S.A. (AIM:NCYT) Trading update and progress against strategy
Trading update and progress against strategy for H1 2022
Novacyt S.A. (AIM:NCYT) Launch of monkeypox assay
Paris, France and Camberley, UK – 28 June 2022 – Novacyt ( EURONEXT GROWTH: ALNOV; AIM: NCYT ), an international specialist in clinical diagnostics, announces the launch of its research-use-only
Novacyt S.A. (AIM:NCYT) DHSC dispute update
Paris, France and Camberley, UK – 16 June 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on its ongoing dispute with
Novacyt S.A. (AIM:NCYT) DHSC dispute update
Paris, France and Camberley, UK – 26 April 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on its ongoing dispute with
Novacyt S.A. (AIM:NCYT) Approval of COVID-19 test under CTDA legislation
Approval of second direct-to-PCR COVID-19 test in the UK under CTDA legislation
Novacyt S.A. (AIM: NCYT) Approval of COVID-19 test under CTDA legislation
Paris, France and Camberley, UK – 17 February 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s PROmate ® COVID-19 2G
Novacyt S.A. (NCYT.L) Strategy and Full Year 2021 Trading Update
Full-year revenue and EBITDA in line with expectations
Novacyt S.A. (NCYT.L) Approval of COVID-19 test under CTDA legislation
Paris, France and Camberley, UK – 26 November 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that, further to the announcement on 2
Novacyt S.A. (NCYT.L) Proposed accounting treatment of DHSC dispute
Proposed accounting treatment of ongoing DHSC dispute in 2021 interim results